NASDAQ:REPH - Recro Pharma Stock Price, News & Analysis

$11.94
0.00 (0.00 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$11.82
Now: $11.94
$12.0850
50-Day Range
$9.31
MA: $11.20
$12.48
52-Week Range
$5.53
Now: $11.94
$12.67
Volume214,694 shs
Average Volume285,219 shs
Market Capitalization$267.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.31
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.91) per share

Profitability

Net Income$-79,720,000.00

Miscellaneous

Employees255
Market Cap$267.79 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.


Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) issued its quarterly earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.29. The specialty pharmaceutical company had revenue of $31.26 million for the quarter, compared to the consensus estimate of $24.06 million. Recro Pharma had a negative return on equity of 472.45% and a negative net margin of 64.26%. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Recro Pharma.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $91-94 million, compared to the consensus revenue estimate of $91.33 million.

What price target have analysts set for REPH?

4 Wall Street analysts have issued 12 month target prices for Recro Pharma's stock. Their predictions range from $7.50 to $20.00. On average, they expect Recro Pharma's share price to reach $12.6250 in the next year. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

Media headlines about REPH stock have been trending negative this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Recro Pharma earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest in August. As of August 31st, there was short interest totalling 880,700 shares, an increase of 35.0% from the July 31st total of 652,600 shares. Based on an average trading volume of 201,300 shares, the days-to-cover ratio is presently 4.4 days. Currently, 4.6% of the company's shares are short sold. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.76%), Engine Capital Management LP (4.92%), Vanguard Group Inc. (4.09%), Renaissance Technologies LLC (3.47%), Panagora Asset Management Inc. (2.03%) and Nuveen Asset Management LLC (1.51%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood, Healthcare Master Fun Broadfin, Scp Vitalife Partners (Israel) and Scp Vitalife Partners Ii Lp. View Institutional Ownership Trends for Recro Pharma.

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Northern Trust Corp, Cadence Capital Management LLC and Strs Ohio. View Insider Buying and Selling for Recro Pharma.

Which major investors are buying Recro Pharma stock?

REPH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, BlackRock Inc., Wedge Capital Management L L P NC, Penn Capital Management Co. Inc., Morgan Stanley and Vanguard Group Inc.. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $11.94.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $267.79 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com/.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2400 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  539
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Coverage Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel